520 件 ・ 関連度順
概要と使いどころ
Apply these opinionated React conventions when writing React 18+ or 19 components: hooks patterns, Server Components, Suspense boundaries, state management, performance memoization, React 19 features (use, form actions).
日本語の概要は準備中です。原文の説明を表示しています。
Red team security mode for OpenClaw. Runs an adversarial audit on demand or nightly — checks exposed ports, credential leaks, file permissions, suspicious processes, and OpenClaw config posture. Assigns a letter grade. Built for macOS deployments.
日本語の概要は準備中です。原文の説明を表示しています。
Diagnose Sentry issues without copy-pasting stack traces. Uses the Composio CLI to pull issue details, events, breadcrumbs, and suspect commits, then maps the frames to local source so the agent can propose a fix directly.
日本語の概要は準備中です。原文の説明を表示しています。
Optimizes application performance. Use when performance requirements exist, when you suspect performance regressions, or when Core Web Vitals or load times need improvement. Use when profiling reveals bottlenecks that need fixing.
日本語の概要は準備中です。原文の説明を表示しています。
**精度验收标准**：凡是"改动不应改变结果"的场合（等价替换、算子/子模块融合、并行切分、 编译与图下发、拷贝消减），都按本标准判"合格 / 不合格"——等价分层（L1 逐位 / L2 数值门 / L3 有损门）+ 三级验收序（① 同配置重跑逐位 → ② 跨配置数值门 + 产物 md5 不变 → ③ 质量门）+ 判据不达标时的排障入口。当用户说"这个算子能不能换个写法/换个 kernel/等价实现/ 无损替换""替换后结果会不会变""怎么证明逐位一致""结果不对""花屏""尾部塌了" "CPU 跑对 NPU 跑不对"，或发现某个 hotspot 占了大头（例如某类算子在阶段里占 90% 以上）想动手时， 都应触发；即使用户只说"这样改有没有把结果改坏""能不能判它是无损的"也应触发。 覆盖：等价分层与判据、满足本标准的实现约定（per-shape 对拍写进实现，把索引/相位/顺序类重写 错误在首次调用抓住）、per-shape 条件性等价（同一改动在不同形状下结论可能不同）、 判据不达标 → `references/silent-failure-localization.md` 排障入口、否决案例的形态学 （换写法未换 kernel / 差异极小仍非逐位 / 等价但 OOM）、以及收益口径的归属（性能数字一律交 `perf-gate`）。 **近义分流**：选量化档 / 特性选档（要不要开量化、开哪一档）→ `dit-perf-opt`； 并行选型（USP / CP / TP 怎么切）→ `dit-parallel-opt`；本技能只判"结果是否被改变"， 不负责选档与选型。
日本語の概要は準備中です。原文の説明を表示しています。
Deep Vue 3 best-practices review and authoring workflow: built-in components (Teleport, Suspense, KeepAlive, Transition), animations, slots, directives, render fns, perf pass. Complements mk:vue.
日本語の概要は準備中です。原文の説明を表示しています。
Vue 3 testing best-practices review: Vitest + Vue Test Utils for components, composables, Pinia, Router, async/Suspense, forms, a11y, plus Playwright E2E strategy. Advisory only.
日本語の概要は準備中です。原文の説明を表示しています。
Use for deep Vue 3 best-practices review, recommendations, and the full ordered authoring workflow — built-in components (Teleport, Suspense, KeepAlive, Transition, TransitionGroup), animation techniques, slots, fallthrough attrs, custom directives, async components, render functions, plugins, and the post-functionality performance pass. Complements mk:vue (the everyday Composition API quick-reference). Invoke for "review my Vue", "Vue best practices", "recommend improvements", or non-trivial feature work needing the ordered workflow.
日本語の概要は準備中です。原文の説明を表示しています。
Use for Vue 3 testing best-practices review and recommendations — designing and auditing Vitest + Vue Test Utils tests for components, composables, Pinia stores, Vue Router, async/Suspense, Teleport, forms, and accessibility, plus Playwright E2E test-design strategy. Advisory/review only — recommends patterns and flags test smells; does not run tests. Complements mk:vue-best-practices (feature code). Invoke for "review my Vue tests", "how should I test this component/composable/store", or "Vue test best practices".
日本語の概要は準備中です。原文の説明を表示しています。
Rembric dashboard UI work (dark monochrome zinc surfaces, lime accent, Geist type, Spectrum data-tables) — building / editing / extending pages, styles, components, modals, tables, filters, pagination, mobile responsive, destructive confirmations. Use when the user asks for changes under `apps/web/src/app/dashboard/` or `apps/web/src/components/dashboard/`, mentions Rembric design tokens (lime, zinc, command bar, StatusPill, hl-lime, data-table), or requests a new dashboard page / form / table.
日本語の概要は準備中です。原文の説明を表示しています。
Describe patterns that may indicate bad-faith or manipulative communication including gish gallop, whataboutism, tone policing, motte-and-bailey, sealioning, lying by omission, deflection, and strategic evasion. Use when the user suspects manipulation, notices repeated non-engagement, wants to analyze debate tactics, or mentions 'bad faith', 'deflection', 'manipulation', 'dodging the question', 'avoiding the issue', 'gaslighting', 'moving goalposts'. Describes behavioral patterns without making psychological diagnoses.
日本語の概要は準備中です。原文の説明を表示しています。
Assesses the quality and completeness of a genome annotation with BUSCO (conserved single-copy ortholog recovery), OMArk (proteome completeness, consistency, and contamination), CheckM2 (prokaryotic completeness/contamination), and a gene-set sanity panel (gene count, mono-exonic fraction, protein-length distribution, mRNA:gene ratio, coding density). Covers the assembly-BUSCO-vs-proteome-BUSCO diagnostic, what BUSCO-Duplicated really means, why gene count is a vanity metric, and the QC of transferred annotations. Use when judging whether an annotation is good enough to publish or submit, diagnosing a suspect annotation, or comparing annotation completeness across pipelines.
日本語の概要は準備中です。原文の説明を表示しています。
Assigns pathogen lineages (SARS-CoV-2 Pangolin UShER mode; Nextclade clade + QC; pango-designation alias resolution) and tracks variant frequencies over time using Nextstrain (Augur + Auspice), wastewater deconvolution (Freyja, COJAC, alcov, lineagespot), lineage-fitness modelling (multinomial logistic), and recombinant detection (3SEQ, RDP4, Bolotie). Covers Pangolin pangolin-data and Nextclade dataset version pinning (mandatory; lineage-defining mutations change with dataset), Freyja barcode forward-only date constraint, ARTIC primer scheme churn (V3/V4/V4.1/V5.3.2/Midnight) with dropout regions, and recombinant X-prefix designation lag. Use when assigning Pango lineages and Nextclade clades to viral consensus sequences, building Nextstrain Augur surveillance pipelines, deconvolving wastewater into lineage frequencies with Freyja, tracking lineage frequencies over time, handling ARTIC primer dropouts, or running surveillance for SARS-CoV-2/influenza/Mpox/RSV/H5N1/measles.
日本語の概要は準備中です。原文の説明を表示しています。
Detects and removes doublets/aggregates from flow, spectral, and mass cytometry before clustering or quantification. Covers FSC-A vs FSC-H singlet discrimination (the Area-Height non-proportionality, not a 1D area gate), FSC-W/SSC width gating, CyTOF Gaussian discrimination parameters (Center/Offset/Width/Residual/Event_length) and DNA intercalator gating, and the residual heterotypic conjugates that survive scatter gating and masquerade as double-positive populations. Use when filtering aggregates before phenotyping, choosing a doublet method for flow vs CyTOF, or diagnosing a suspicious double-positive cluster.
日本語の概要は準備中です。原文の説明を表示しています。
Creates DE-specific diagnostic and result visualizations using DESeq2/edgeR built-in functions and lightweight ggplot2 wrappers. Covers MA plot (with the shrunken-LFC compression effect), volcano (with the apeglm caveat that p-values are unchanged), PCA on VST/rlog (never raw counts), sample distance heatmaps, top-DE-gene heatmaps with the row-scaling trap, dispersion / BCV plot interpretation, p-value histogram diagnostics, plotCounts for individual genes, blind=TRUE vs FALSE rationale, and the n=3 visualization stake. Use when generating DE diagnostic plots, choosing VST vs rlog for visualization, troubleshooting suspicious plot patterns (shifted MA cloud, batch-dominated PCA, anti-conservative p-value histogram), or building a standard QC figure panel.
日本語の概要は準備中です。原文の説明を表示しています。
Runs JACKS (Joint Analysis of CRISPR/Cas9 Knockout Screens; Allen et al 2019 Genome Research) which models per-sgRNA log-fold-change as the product of a treatment-dependent gene-essentiality term and a treatment-independent guide-efficacy term. Covers the Bayesian decomposition math, the hierarchical efficacy prior shared across screens performed with the same library, when JACKS outperforms MAGeCK (multi-screen joint analysis, libraries with broad efficacy variance) and when it does not (single screen, novel libraries with no prior efficacy), library-reuse efficacy transfer, downstream essentiality interpretation, and the 2.5x sample-size reduction enabled by efficacy-aware testing. Use when running multiple screens with the same library, when guide-level noise is suspected to dominate per-gene signal, when reusing published essentiality reference screens for efficacy priors, or when comparing screens performed across cell lines that share library but differ biologically.
日本語の概要は準備中です。原文の説明を表示しています。
Resolve the architecture of focal oncogene amplifications — extrachromosomal DNA (ecDNA), breakage-fusion-bridge (BFB) cycles, homogeneously staining regions (HSR), and linear amplification — from whole-genome sequencing with AmpliconArchitect, the AmpliconSuite pipeline, and AmpliconClassifier. Covers copy-number seed selection, breakpoint-graph reconstruction, balanced-flow optimization, ecDNA classification, and the limits of depth-only amplification calls. Use when a focal amplification needs structural characterization, when distinguishing ecDNA from chromosomal amplification, suspecting ecDNA-driven oncogene amplification or therapy resistance, or selecting copy-number seeds for amplicon reconstruction.
日本語の概要は準備中です。原文の説明を表示しています。
Detect and adjust for horizontal pleiotropy in two-sample Mendelian randomization by distinguishing uncorrelated (UHP) from correlated (CHP) pleiotropy and choosing among Egger, MR-PRESSO, MR-RAPS, CAUSE, LHC-MR, LCV, MR-Clust, MR-Mix, and contamination-mixture methods. Use when validating an MR causal claim, running the STROBE-MR sensitivity battery, suspecting a shared heritable confounder, working under weak-instrument or polygenic-exposure regimes, or reconciling discordant estimates across robust methods.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends measuring serum sodium several times during the first 5–14 days after transsphenoidal surgery to detect and manage electrolyte disturbances such as postoperative hyponatremia and diabetes insipidus. Use when managing a post-TSS Cushing’s syndrome patient in the early recovery phase; triggers include postoperative day 5–10 hyponatremia, polyuria, fluid intake‑output imbalance, or suspected diabetes insipidus.
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests radiation therapy or radiosurgery for adult patients with Cushing's disease who have failed transsphenoidal surgery (TSS) or have recurrent disease after initial remission. Consider when postoperative urinary free cortisol or late-night salivary cortisol remains elevated, or when clinical recurrence is suspected.
日本語の概要は準備中です。原文の説明を表示しています。
Work up Malignancy-Associated Hypercalcemia (MAH) — distinguish humoral hypercalcemia of malignancy (HHM, PTHrP-driven), local osteolytic hypercalcemia, 1,25(OH)2D-mediated lymphoma hypercalcemia, ectopic PTH secretion, and multiple myeloma — and pick the right confirmatory tests and therapy direction. Trigger when a clinician asks "is this hypercalcemia from cancer", "PTHrP positive what now", "hypercalcemia in lung cancer / breast cancer / lymphoma / myeloma", "humoral hypercalcemia of malignancy", "MAH workup", or any hypercalcemia case with suppressed PTH and a known or suspected malignancy.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends using radiation therapy for corticotroph adenomas in Cushing's disease when imaging shows invasive features or mass‑effect concerns such as cavernous sinus invasion, suprasellar extension, or knobby protrusion. Consider RT when postoperative medical therapy has normalized cortisol but tumor progression or residual invasive disease is suspected.
日本語の概要は準備中です。原文の説明を表示しています。
This skill recommends lifelong follow-up tests for cardiac myxoma and associated disease (testicular tumors, acromegaly, thyroid lesions) in patients with Carney complex. Use when managing a Cushing’s syndrome patient with a confirmed or suspected Carney complex diagnosis (e.g., spotty skin lentigines, cardiac myxoma, endocrine tumors).
日本語の概要は準備中です。原文の説明を表示しています。
This skill suggests targeted therapies (somatostatin analogs or tyrosine kinase inhibitors) to treat ectopic ACTH syndrome when ectopic ACTH secretion is confirmed or strongly suspected. Use when triggers include occult or metastatic ectopic ACTH secretion, very severe ACTH‑dependent disease uncontrolled by medical therapy, or when surgery is not possible or noncurative.
日本語の概要は準備中です。原文の説明を表示しています。